当前位置: 首页 > 期刊 > 《医学信息》 > 2016年第17期
编号:12874196
脂蛋白相关磷脂酶A2的研究概况(6)
http://www.100md.com 2016年4月30日 《医学信息》 2016年第17期
     [16]Ishihara M, Iwasaki T, Nagano M, et al. Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients[J]. Hum Genet, 2004, 49: 302-307.

    [17]Osoegawa M, Niino M, Ochi H, et al. Platelet-activating factor acetylhydrolase gene polymorphism and its activity in Japanese patients with multiple sclerosis[J]. Neuroimmunol, 2004, 5, 150(1-2): 150-156.

    [18]Jang Y, Kim OY, Koh SJ, et al. The Val279Phe variant of the lipoprotein- associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men[J]. Clin Endocrinol Metab, 2006, 91: 3521-3527.

    [19]Sutton BS, Crosslin DR, Shah SH, et al. Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets[J]. Hum Mol Genet, 2008, 17: 1318-1328.

    [20]Liu PY, Li YH, Wu HL, et al. Platelet-activating factor-acetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction[J]. Thromb Haemost, 2006, 4: 1023-1028.

    [21] The STABILITY Investigators,Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease[J].The New England Journal of Medicine,2014,Mar.

    编辑/周芸霏, http://www.100md.com(田瑞)
上一页1 2 3 4 5 6